Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

Note 2: The first analysis in the table (i.e., HPV 16- or 18-related CIN 2/3, AIS or worse) was the primary endpoint of the vaccine development plan. Note 3: FUTURE I refers to Protocol 013; FUTURE II refers to Protocol 015. ---------------------------------------------------------------------- GARDASIL was efficacious against HPV disease caused by each of the 4 vaccine HPV types. In a pre-defined analysis, the efficacy of GARDASIL against HPV 16/18-related disease was 100% (95% CI: 87.9%, 100.0%) for CIN 3 or AIS and 100% (95% CI: 55.5%, 100.0%) for VIN 2/3 or VaIN 2/3. The efficacy of GARDASIL against HPV 6-, 11-, 16-, and 18-related VIN 1 or VaIN 1 was 100% (95% CI: 75.8%, 100.0%). These analyses were conducted in the PPE population that consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naive (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). Efficacy in Subjects with Current or Prior Infection GARDASIL is a prophylactic vaccine. There was no clear evidence of protection from disease caused by HPV types for which subjects were PCR positive and/or seropositive at baseline. Individuals who were already infected with 1 or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV types. General Population Impact The general population of young American women includes women who are HPV-naive (PCR negative and seronegative) and women who are HPV-non-naive (PCR positive and/or seropositive), some of whom have HPV-related disease. The clinical trials population approximated the general population of American women with respect to prevalence of HPV infection and disease at enrollment. Analyses were conducted to evaluate the overall impact of GARDASIL w
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, Inc., ... the treatment of chronic pain, announced today that it ... the position of  Senior Director of Clinical Development. ... James has established and led successful global clinical operations ... , to facilitate the clinical development of numerous therapeutics ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
(Date:9/18/2014)... MARLBOROUGH, Mass. , Sept. 18, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... Executive Officer, Dr. Geert Cauwenbergh , ... Annual BioPharm America™ Conference on Wednesday, September ...
Breaking Medicine Technology:Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... of evaluable heavily-pretreated patients in the high dose ... tolerated overall.DALLAS, March 5 ACCESS PHARMACEUTICALS, ... safety and efficacy results from its Phase 2 ... heavily pretreated ovarian cancer patients. In this monotherapy ...
... March 4 A new study by researchers at ... essential B vitamins, including B6, B12, and folic acid, ... of the leading causes of vision loss among older ... key omega-3 fatty acids and phytosterols, are also contained ...
Cached Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2
(Date:9/18/2014)... has proven it true: exercise is good for you. ... that exercise may have an added benefit for cancer ... mouse model of melanoma, found that combining exercise with ... Joseph Libonati, an associate professor in the School of ... Translational Nursing Research, was the senior author on the ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded ... million grant to the Los Angeles Biomedical Research Institute ... of a vaccine to protect patients from the healthcare-related ... (MRSA). , The National Institute of Allergy ... grant to LA BioMed infectious disease specialists John E. ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... NY -- Vivian W. Pinn, MD will be awarded ... the 20th Annual Congress on Women,s Health, March 16-18, ... providers from across the country will gather at the ... advances in diagnosis and management, and innovative translational research ...
... rare in the United States but the third-leading cause of ... infections like chronic hepatitis, but the link is poorly understood. ... mechanism in mice that triggers inflammation in the liver and ... demonstrated in a mouse model that a particular micro-RNA (miR-124) ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Depression and ... intensive care unit after treatment for a potentially deadly condition ... findings may also apply to ICU patients with other types ... machines, according to the researchers. "When people are discharged ...
... cells in the blood appears to have no relationship to ... breast cancer, according to new research from Fox Chase Cancer ... cells may signal that the disease has spread to other ... The results will be presented on Friday, December 9 ...
... DEC. 9, 2011] The investigation of a 2009 multistate ... an important cause of bacterial gastrointestinal illness, led to ... in Clinical Infectious Diseases and available ... recommendations for prevention, including a stronger message for consumers: ...
... Children who suffer from persistent or recurring chronic pain ... risk of developing internalizing symptoms such as anxiety, in response ... chronic pain in children and adolescents in 20 years, a ... from chronic pain and that girls suffer more frequently from ...
Cached Medicine News:Health News:Dr. Vivian W. Pinn to receive inaugural Bernadine Healy Award 2Health News:Researchers identify a novel therapeutic approach for liver cancer 2Health News:Depression, Disability Can Follow ICU Care: Study 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 3Health News:Ready-to-bake cookie dough not ready-to-eat, study of E. coli outbreak finds 2Health News:Chronic pain in children and adolescents becoming more common 2
Large image and wide angle design for transurethral examination and treatment of the ureter and renal pelvis....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
Calculate accurate growth percentiles and Z scores using the latest CDC growth charts....
PDA-version of the leading portable drug reference....
Medicine Products: